Research is being conducted on the effectiveness of a low, fixed dose of rasburicase. The medication is being studied in the context of preventing hyperuricemia and managing tumor lysis syndrome, a potential side effect of cancer treatment. The investigation may have implications for optimizing dosing and improving access to effective cancer medicines.